TTE is considered MEDICALLY NECESSARY for the following indications (selection of preserved document sections):
General cardiac evaluation: When history, physical examination, or routine laboratory tests suggest or cannot eliminate cardiac disease (e.g., dyspnea, edema with suspected elevated central venous pressure), TTE is the preferred initial diagnostic test.
Hypertensive heart disease: Evaluation of cardiac effects of systemic hypertension, including assessment for left ventricular hypertrophy or mass to guide therapy in young or borderline hypertensive individuals.
Acute myocardial infarction and ischemia: Evaluation of regional wall motion, right ventricular ischemia/infarction, diagnosis and complications of acute MI (mural thrombi, papillary muscle dysfunction/rupture, septal defects, aneurysm) and assessment of chest pain when ECG/laboratory markers are nondiagnostic.
Repeat TTE frequency after acute infarction should be documented and dictated by clinical course.
Cardiotoxic exposure monitoring: Baseline complete TTE prior to administration of cardiotoxic agents with repeat studies as clinically indicated (tests performed bimonthly during chemotherapy and at approximately 6 months following therapy are generally appropriate).
Transplant and rejection monitoring: Baseline and serial TTE for donor selection, recipient matching, and monitoring allograft function; typically weekly for the first 4–8 weeks post-transplant and approximately twice yearly in stable chronic recipients.
Valvular disease: Primary choice for evaluation of native valvular pathology and hemodynamic effect; Doppler may be required.
It is not medically necessary to repeat these examinations more than once per year when clinical status is stable.
Prosthetic valves: Post-implant baseline TTE to establish structural and hemodynamic profile with reassessment at 3–6 months; thereafter reassessment for suspected dysfunction, thrombosis, or change in clinical status.
Endocarditis: Diagnostic evaluation of suspected infective endocarditis and its complications or sequelae; examination frequency dictated by clinical course.
Pericardial disease: Detection and quantification of pericardial effusion, characterization of hemodynamic consequences, diagnosis of constrictive versus restrictive disease, and as an adjunct during pericardial fluid removal.
Great vessel abnormalities: Evaluation of acute or chronic aortic pathology, routine yearly evaluation for severe aortic stenosis/regurgitation when it informs care, assessment of ascending aortic dilation, and evaluation of pulmonary artery segments and vena cavae abnormalities.
Congenital heart disease: Diagnosis and serial noninvasive assessment of most congenital heart diseases with Doppler; when stable, more than annual assessment requires documentation of medical necessity.
Suspected cardiac thrombi/embolic sources: Evaluation for cardiovascular sources of embolic events (PFO/ASD, atrial/ventricular thrombus, intracardiac tumor) in patients with abrupt occlusion of major arteries or neurological events without other cause.
Cardiac tumors: Diagnosis and serial monitoring of cardiac tumors and masses.
Critically ill and trauma patients: Evaluation of suspected aortic or central pulmonary pathology, cardiac contusion, pericardial effusion, and assessment of volume status; frequency dictated by clinical circumstances.
Arrhythmias and palpitations: Evaluate cardiac function in patients with arrhythmias when there is evidence of heart disease (e.g., atrial fibrillation/flutter).